Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy
Autore:
Hesketh, PJ; Crews, JR; Cohen, R; Blackburn, LM; Friedman, CJ;
Indirizzi:
St Elizabeths Med Ctr, Div Hematol Oncol, Boston, MA 02135 USA St Elizabeths Med Ctr Boston MA USA 02135 tol Oncol, Boston, MA 02135 USA Raleigh Internal Med, Raleigh, NC USA Raleigh Internal Med Raleigh NC USA aleigh Internal Med, Raleigh, NC USA Univ Virginia, Med Ctr, Charlottesville, VA USA Univ Virginia Charlottesville VA USA a, Med Ctr, Charlottesville, VA USA SmithKline Beecham Pharmaceut, Collegeville, PA USA SmithKline Beecham Pharmaceut Collegeville PA USA , Collegeville, PA USA
Titolo Testata:
CANCER JOURNAL
fascicolo: 3, volume: 6, anno: 2000,
pagine: 157 - 161
SICI:
1528-9117(200005/06)6:3<157:AEOSOG>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
5-HT3 RECEPTOR ANTAGONISTS; CISPLATIN-INDUCED EMESIS; PROSPECTIVE RANDOMIZED TRIAL; DOUBLE-BLIND; INTRAVENOUS ONDANSETRON; INDUCED NAUSEA; DOLASETRON MESYLATE; PLUS DEXAMETHASONE; DELAYED NAUSEA; PREVENTION;
Keywords:
granisetron; vomiting; nausea; cyclophosphamide; carboplatin; dexamethasone; methylprednisolone;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
36
Recensione:
Indirizzi per estratti:
Indirizzo: Hesketh, PJ St Elizabeths Med Ctr, Div Hematol Oncol, 736 Cambridge St, Boston, MA 02135 USA St Elizabeths Med Ctr 736 Cambridge St Boston MA USA 02135 USA
Citazione:
P.J. Hesketh et al., "Antiemetic efficacy of single-dose oral granisetron (1 mg vs 2 mg) with moderately emetogenic chemotherapy", CANCER J, 6(3), 2000, pp. 157-161

Abstract

PURPOSETo compare the efficacy of oral granisetron, 1 mg and 2 mg, administered as one dose in patients who receive moderately emetogenic chemotherapy. PATIENTS AND METHODSChemotherapy-naive patients, scheduled to receive intravenous cyclophosphamide (500 to 1200 mg/m(2)) or carboplatin (greater than or equal to 300 mg/m(2)), were stratified by dexamethasone/ methylprednisolone use (+ DEX, n =92) or nonuse (- DEX, n = 5). Patients were randomized to one dose of either 1 mg (n = 48) or 2 mg (n = 49) of granisetron administered 60 minutes before chemotherapy. Known important prognostic variables (gender, age, alcohol) were well balanced between groups. RESULTSUsing the most rigorous criterion of total control (no emetic episodes, nonausea, no rescue therapy during the first 24 hours), response rates were 54.2% (26/48) and 57.1% (28/49) in patients receiving 1 mg and 2 mg of granisetron, respectively (95% confidence interval, -0.17, 0.23). Total controlrates in patients who received 1 mg and 2 mg of granisetron + DEX were also comparable: 57.8% (26/45) and 55.3% (26/47), respectively. Response rateswere similar for the parameters of nausea, emesis, and complete response (no emetic episodes, no more than mild nausea, no antiemetic rescue). Among all patients, one (2.1%) who received 1 mg of granisetron and three (6.1%) who received 2 mg experienced severe nausea. The proportions of 1- and 2-mg-treated patients who received rescue therapy within the first 24 hours were 31.3% (15/48) and 34.7% (17/49), respectively. Reported adverse experiences were generally mild in severity. DISCUSSIONThe results of this trial demonstrate good control of emesis with a single1-mg dose of oral granisetron, with efficacy that compares favorably with that of a 2-mg dose.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/12/20 alle ore 03:44:55